Expression of the Bcl-3 Proto-oncogene Suppresses P53 Activation

Overview

Journal Genes Dev

Specialty Molecular Biology

Date 2005 Dec 31

PMID 16384933

Citations 71

Authors

David Kashatus

Patricia Cogswell

Albert S Baldwin

Affiliations

Soon will be listed here.

Abstract

While Bcl-3 expression in cancer was originally thought to be limited to B-cell lymphomas with a 14;19 chromosomal translocation, more recent evidence indicates that expression of this presumptive oncoprotein is significantly more widespread in cancer. However, an oncogenic role for Bcl-3 has not been clearly identified. Experiments presented here indicate that Bcl-3 is inducible by DNA damage and is required for the induction of Hdm2 gene expression and the suppression of persistent p53 activity. Furthermore, constitutive expression of Bcl-3 suppresses DNA damage-induced p53 activation and inhibits p53-induced apoptosis through a mechanism that is at least partly dependent on the up-regulation of Hdm2. The results provide insight into a mechanism whereby altered expression of Bcl-3 leads to tumorigenic potential. Since Bcl-3 is required for germinal center formation, these results suggest functional similarities with the unrelated Bcl-6 oncoprotein in suppressing potential p53-dependent cell cycle arrest and apoptosis in response to somatic hypermutation and class switch recombination.

Citing Articles

Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3.

Daams R, Tran T, Jemaa M, Sime W, Mickeviciute R, Ek S Cell Death Dis. 2024; 15(9):690.

PMID: 39327470 PMC: 11427694. DOI: 10.1038/s41419-024-07067-w.

Suppression of Bcl3 Disrupts Viability of Breast Cancer Cells through Both p53-Dependent and p53-Independent Mechanisms via Loss of NF-κB Signalling.

Turnham D, Smith H, Clarkson R Biomedicines. 2024; 12(1).

PMID: 38255248 PMC: 10813424. DOI: 10.3390/biomedicines12010143.

Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age.

Seaton G, Smith H, Brancale A, Westwell A, Clarkson R Mol Cancer. 2024; 23(1):7.

PMID: 38195591 PMC: 10775530. DOI: 10.1186/s12943-023-01922-8.

p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).

Milani D, Caruso L, Zauli E, Al Owaifeer A, Secchiero P, Zauli G Front Pharmacol. 2022; 13:871583.

PMID: 35721196 PMC: 9201997. DOI: 10.3389/fphar.2022.871583.

Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.

Carr D, Zein A, Coulombe J, Jiang T, Cabrita M, Ward G Breast Cancer Res. 2022; 24(1):40.

PMID: 35681213 PMC: 9185916. DOI: 10.1186/s13058-022-01536-w.

References

Wan Y, DeGregori J . The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. Immunity. 2003; 18(3):331-42. DOI: 10.1016/s1074-7613(03)00053-0. View

Schwarz E, Krimpenfort P, Berns A, Verma I . Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 1997; 11(2):187-97. DOI: 10.1101/gad.11.2.187. View

Rocha S, Martin A, Meek D, Perkins N . p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol. 2003; 23(13):4713-27. PMC: 164841. DOI: 10.1128/MCB.23.13.4713-4727.2003. View

Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville M . NF- kappa B2/p100 induces Bcl-2 expression. Leukemia. 2003; 17(7):1349-56. DOI: 10.1038/sj.leu.2402982. View

Watanabe N, Wachi S, Fujita T . Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination. J Biol Chem. 2003; 278(28):26102-10. DOI: 10.1074/jbc.M303518200. View

Espinosa J, Verdun R, Emerson B . p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell. 2003; 12(4):1015-27. DOI: 10.1016/s1097-2765(03)00359-9. View

Jeffers J, Parganas E, Lee Y, Yang C, Wang J, Brennan J . Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003; 4(4):321-8. DOI: 10.1016/s1535-6108(03)00244-7. View

Villunger A, Michalak E, Coultas L, Mullauer F, Bock G, Ausserlechner M . p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003; 302(5647):1036-8. DOI: 10.1126/science.1090072. View

Kucharczak J, Simmons M, Fan Y, Gelinas C . To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene. 2003; 22(56):8961-82. DOI: 10.1038/sj.onc.1207230. View

10.

Thornburg N, Pathmanathan R, Raab-Traub N . Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003; 63(23):8293-301. View

11.

Chipuk J, Kuwana T, Bouchier-Hayes L, Droin N, Newmeyer D, Schuler M . Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004; 303(5660):1010-4. DOI: 10.1126/science.1092734. View

12.

Canoz O, Rassidakis G, Admirand J, Medeiros L . Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol. 2004; 17(8):911-7. DOI: 10.1038/modpathol.3800140. View

13.

Hayden M, Ghosh S . Signaling to NF-kappaB. Genes Dev. 2004; 18(18):2195-224. DOI: 10.1101/gad.1228704. View

14.

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A . The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005; 102(3):731-6. PMC: 545522. DOI: 10.1073/pnas.0405495102. View

15.

Bond G, Hu W, Levine A . MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005; 5(1):3-8. DOI: 10.2174/1568009053332627. View

16.

Cogswell P, Guttridge D, Funkhouser W, Baldwin Jr A . Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000; 19(9):1123-31. DOI: 10.1038/sj.onc.1203412. View

17.

Ryan K, Ernst M, Rice N, Vousden K . Role of NF-kappaB in p53-mediated programmed cell death. Nature. 2000; 404(6780):892-7. DOI: 10.1038/35009130. View

18.

Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T . Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000; 288(5468):1053-8. DOI: 10.1126/science.288.5468.1053. View

19.

Hay T, Meek D . Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 2000; 478(1-2):183-6. DOI: 10.1016/s0014-5793(00)01850-0. View

20.

Hubinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, Singer B . CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 2001; 20(5):590-8. DOI: 10.1038/sj.onc.1204128. View